TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Control of Myopia Progression in Myopic Children Using Simultaneous Vision Approach
Brief Summary: To determine if the 'Defocus Incorporated Soft Contact' (DISC) lens slows myopia progression in Hong Kong schoolchildren using simultaneous vision approach.


Options:
A: Intervention Type: DRUG; Name: Atropine Eye drops; Assigned to Arm(s): N/A
B: Arm Label: ortho-k and 0.01% atropine eye drops; Type: EXPERIMENTAL; Interventions: Drug: 0.01% atropine eye drops, Device: ortho-k | Arm Label: ortho-k; Type: ACTIVE_COMPARATOR; Interventions: Device: ortho-k | Intervention Type: DRUG; Name: 0.01% atropine eye drops; Assigned to Arm(s): ortho-k and 0.01% atropine eye drops | Intervention Type: DEVICE; Name: ortho-k; Assigned to Arm(s): ortho-k, ortho-k and 0.01% atropine eye drops
C: Arm Label: Progressive Addition Lenses (PALs); Type: EXPERIMENTAL; Interventions: Other: Progressive Addition Lenses | Arm Label: Single Vision Lenses; Type: ACTIVE_COMPARATOR; Interventions: Other: single vision lenses | Intervention Type: OTHER; Name: Progressive Addition Lenses; Assigned to Arm(s): Progressive Addition Lenses (PALs) | Intervention Type: OTHER; Name: single vision lenses; Assigned to Arm(s): Single Vision Lenses
D: Arm Label: single vision soft contact lens; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Defocus Incorporated Soft Contact (DISC) lens; Type: EXPERIMENTAL; Interventions: Device: Defocus Incorporated Soft Contact (DISC) lens | Intervention Type: DEVICE; Name: Defocus Incorporated Soft Contact (DISC) lens; Assigned to Arm(s): Defocus Incorporated Soft Contact (DISC) lens

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: An Assessment of Delirium in Mechanically Ventilated Patients Undergoing Daily Awakening From Sedation
Brief Summary: The overall purpose of this trial is to assess the relationship between a daily awakening from sedation and the prevalence of delirium, and in doing so better characterize delirium in the ICU.


Options:
A: N/A
B: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Rivastigmine | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Rivastigmine; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 2
C: Arm Label: Dexmedetomidine group; Type: ACTIVE_COMPARATOR; Interventions: Drug: Dexmedetomidine | Arm Label: Lorazepam group; Type: ACTIVE_COMPARATOR; Interventions: Drug: Lorazepam | Intervention Type: DRUG; Name: Dexmedetomidine; Assigned to Arm(s): Dexmedetomidine group | Intervention Type: DRUG; Name: Lorazepam; Assigned to Arm(s): Lorazepam group
D: Arm Label: Sedated mechanically ventilated patients; Type: N/A; Interventions: N/A

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: An Open-label Study to Assess the Safety and Reactogenicity of GlaxoSmithKline Biologicals' Inactivated Poliomyelitis Vaccine Poliorix Administered as a Booster Dose at 18-24 Months of Age in Healthy Toddlers in China.
Brief Summary: The study will evaluate the safety and reactogenicity of PoliorixTM given as a single booster dose to Chinese children at 18-24 months of age.


Options:
A: Arm Label: Poliorix Group; Type: EXPERIMENTAL; Interventions: Biological: Poliorix™ | Arm Label: Control Group; Type: ACTIVE_COMPARATOR; Interventions: Biological: Oral Poliovirus vaccine | Intervention Type: BIOLOGICAL; Name: Poliorix™; Assigned to Arm(s): Poliorix Group | Intervention Type: BIOLOGICAL; Name: Oral Poliovirus vaccine; Assigned to Arm(s): Control Group
B: Arm Label: Group A; Type: EXPERIMENTAL; Interventions: Biological: Inactivated Poliomyelitis vaccine (IMOVAX) | Arm Label: Group B; Type: ACTIVE_COMPARATOR; Interventions: Biological: Inactivated Poliomyelitis vaccine (IMOVAX) | Intervention Type: BIOLOGICAL; Name: Inactivated Poliomyelitis vaccine (IMOVAX); Assigned to Arm(s): Group A | Intervention Type: BIOLOGICAL; Name: Inactivated Poliomyelitis vaccine (IMOVAX); Assigned to Arm(s): Group B
C: Arm Label: POLIORIX GROUP; Type: EXPERIMENTAL; Interventions: Biological: PoliorixTM | Intervention Type: BIOLOGICAL; Name: PoliorixTM; Assigned to Arm(s): POLIORIX GROUP
D: Arm Label: Group A; Type: EXPERIMENTAL; Interventions: Biological: Inactivated types 1, 2, and 3 poliovirus, D antigens | Arm Label: Group B; Type: ACTIVE_COMPARATOR; Interventions: Biological: Inactivated types 1, 2, and 3 poliovirus, D antigens | Intervention Type: BIOLOGICAL; Name: Inactivated types 1, 2, and 3 poliovirus, D antigens; Assigned to Arm(s): Group A | Intervention Type: BIOLOGICAL; Name: Inactivated types 1, 2, and 3 poliovirus, D antigens; Assigned to Arm(s): Group B

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: An Open-label Study to Assess the Safety and Reactogenicity of GlaxoSmithKline Biologicals' Inactivated Poliomyelitis Vaccine Poliorix Administered as a Booster Dose at 18-24 Months of Age in Healthy Toddlers in China.
Brief Summary: The study will evaluate the safety and reactogenicity of PoliorixTM given as a single booster dose to Chinese children at 18-24 months of age.


Options:
A: Arm Label: Group A (Sequential 1): IPV-OPV-OPV; Type: EXPERIMENTAL; Interventions: Biological: Injectable inactivated types 1, 2 and 3 poliovirus + Live oral Polio | Arm Label: Group B (Sequential 2): IPV-IPV-OPV; Type: EXPERIMENTAL; Interventions: Biological: Injectable inactivated types 1, 2 and 3 poliovirus + Live oral Polio | Arm Label: Group C (Reference): OPV-OPV-OPV; Type: EXPERIMENTAL; Interventions: Biological: Live oral poliovirus type 1, 2 and 3 | Intervention Type: BIOLOGICAL; Name: Injectable inactivated types 1, 2 and 3 poliovirus + Live oral Polio; Assigned to Arm(s): Group A (Sequential 1): IPV-OPV-OPV | Intervention Type: BIOLOGICAL; Name: Injectable inactivated types 1, 2 and 3 poliovirus + Live oral Polio; Assigned to Arm(s): Group B (Sequential 2): IPV-IPV-OPV | Intervention Type: BIOLOGICAL; Name: Live oral poliovirus type 1, 2 and 3; Assigned to Arm(s): Group C (Reference): OPV-OPV-OPV
B: Arm Label: POLIORIX GROUP; Type: EXPERIMENTAL; Interventions: Biological: PoliorixTM | Intervention Type: BIOLOGICAL; Name: PoliorixTM; Assigned to Arm(s): POLIORIX GROUP
C: Intervention Type: BIOLOGICAL; Name: Inactivated Polio Vaccine given at an accelerated schedule; Assigned to Arm(s): N/A
D: Arm Label: Poliorix Group; Type: EXPERIMENTAL; Interventions: Biological: Poliorix™ | Arm Label: Control Group; Type: ACTIVE_COMPARATOR; Interventions: Biological: Oral Poliovirus vaccine | Intervention Type: BIOLOGICAL; Name: Poliorix™; Assigned to Arm(s): Poliorix Group | Intervention Type: BIOLOGICAL; Name: Oral Poliovirus vaccine; Assigned to Arm(s): Control Group

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Pilot Study to Test the Feasibility and the Efficacy of the German Language Adapted PRO-SELF© Plus Pain Control Program, an Educational Intervention Directed at Patients and Their Family Caregivers to Reduce Cancer Pain and Related Symptoms
Brief Summary: The purpose of this pilot study is to refine and test an advanced and adapted German version of the PRO-SELF© Plus Pain Control Program (PCP), an educational intervention directed at cancer pain patients and their families to enhance their pain self management abilities, and to calculate effect sizes for the planning of a sufficiently powered randomized controlled trial (RCT).


Options:
A: Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Intervention; Type: EXPERIMENTAL; Interventions: Other: Psycho-educational intervention | Intervention Type: OTHER; Name: Psycho-educational intervention; Assigned to Arm(s): Intervention
B: Arm Label: German PRO-SELF(c) Plus PCP; Type: EXPERIMENTAL; Interventions: Behavioral: German PRO-SELF(c) Plus Pain Control Program (PCP) | Arm Label: Standard Care; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: German PRO-SELF(c) Plus Pain Control Program (PCP), Other: Standard Care | Intervention Type: BEHAVIORAL; Name: German PRO-SELF(c) Plus Pain Control Program (PCP); Assigned to Arm(s): German PRO-SELF(c) Plus PCP, Standard Care | Intervention Type: OTHER; Name: Standard Care; Assigned to Arm(s): Standard Care
C: Arm Label: Telephone counseling; Type: EXPERIMENTAL; Interventions: Behavioral: Telephone counseling | Arm Label: Education; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Education | Intervention Type: BEHAVIORAL; Name: Telephone counseling; Assigned to Arm(s): Telephone counseling | Intervention Type: BEHAVIORAL; Name: Education; Assigned to Arm(s): Education
D: Intervention Type: PROCEDURE; Name: management of therapy complications; Assigned to Arm(s): N/A | Intervention Type: PROCEDURE; Name: pain therapy; Assigned to Arm(s): N/A | Intervention Type: PROCEDURE; Name: psychosocial assessment and care; Assigned to Arm(s): N/A | Intervention Type: PROCEDURE; Name: quality-of-life assessment; Assigned to Arm(s): N/A

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Randomized Trial: Maternal Vitamin D Supplementation to Prevent Childhood Asthma (VDAART)
Brief Summary: Vitamin D supplementation given to pregnant women will prevent asthma in their offspring and children.


Options:
A: Arm Label: Vitamin D treatment; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Vitamin D 3 cholecalciferol, Dietary Supplement: Vitamin D3 | Arm Label: placebo; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: Vitamin D3 | Intervention Type: DIETARY_SUPPLEMENT; Name: Vitamin D 3 cholecalciferol; Assigned to Arm(s): Vitamin D treatment | Intervention Type: DIETARY_SUPPLEMENT; Name: Vitamin D3; Assigned to Arm(s): Vitamin D treatment, placebo
B: Arm Label: Group A; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: Placebo | Arm Label: Group B; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Vitamin D3 (cholecalciferol), Dietary Supplement: Placebo | Arm Label: Group C; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Vitamin D3 (cholecalciferol), Dietary Supplement: Placebo | Arm Label: Group D; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Vitamin D3 (cholecalciferol), Dietary Supplement: Placebo | Arm Label: Group E; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Vitamin D3 (cholecalciferol) | Intervention Type: DIETARY_SUPPLEMENT; Name: Vitamin D3 (cholecalciferol); Assigned to Arm(s): Group B, Group C, Group D, Group E | Intervention Type: DIETARY_SUPPLEMENT; Name: Placebo; Assigned to Arm(s): Group A, Group B, Group C, Group D
C: Arm Label: choecalciferol; Type: EXPERIMENTAL; Interventions: Dietary Supplement: cholecalciferol | Arm Label: placebo; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: placebo | Intervention Type: DIETARY_SUPPLEMENT; Name: cholecalciferol; Assigned to Arm(s): choecalciferol | Intervention Type: DIETARY_SUPPLEMENT; Name: placebo; Assigned to Arm(s): placebo
D: Arm Label: monitored group; Type: EXPERIMENTAL; Interventions: Dietary Supplement: monitored vit D supplementation | Arm Label: standard group; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: standard vit D supplementation | Intervention Type: DIETARY_SUPPLEMENT; Name: monitored vit D supplementation; Assigned to Arm(s): monitored group | Intervention Type: DIETARY_SUPPLEMENT; Name: standard vit D supplementation; Assigned to Arm(s): standard group

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Randomized Trial: Maternal Vitamin D Supplementation to Prevent Childhood Asthma (VDAART)
Brief Summary: Vitamin D supplementation given to pregnant women will prevent asthma in their offspring and children.


Options:
A: Arm Label: Regimen A; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Regimen A calcium and iron/folic acid | Arm Label: Regimen B; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: Regimen B calcium and iron/folic acid | Intervention Type: DIETARY_SUPPLEMENT; Name: Regimen A calcium and iron/folic acid; Assigned to Arm(s): Regimen A | Intervention Type: DIETARY_SUPPLEMENT; Name: Regimen B calcium and iron/folic acid; Assigned to Arm(s): Regimen B
B: Arm Label: Vitamin D; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: Cholecalciferol D3 | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo tablet | Intervention Type: DIETARY_SUPPLEMENT; Name: Cholecalciferol D3; Assigned to Arm(s): Vitamin D | Intervention Type: OTHER; Name: Placebo tablet; Assigned to Arm(s): Placebo
C: Arm Label: Vitamin D treatment; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Vitamin D 3 cholecalciferol, Dietary Supplement: Vitamin D3 | Arm Label: placebo; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: Vitamin D3 | Intervention Type: DIETARY_SUPPLEMENT; Name: Vitamin D 3 cholecalciferol; Assigned to Arm(s): Vitamin D treatment | Intervention Type: DIETARY_SUPPLEMENT; Name: Vitamin D3; Assigned to Arm(s): Vitamin D treatment, placebo
D: Arm Label: Group A; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: Placebo | Arm Label: Group B; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Vitamin D3 (cholecalciferol), Dietary Supplement: Placebo | Arm Label: Group C; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Vitamin D3 (cholecalciferol), Dietary Supplement: Placebo | Arm Label: Group D; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Vitamin D3 (cholecalciferol), Dietary Supplement: Placebo | Arm Label: Group E; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Vitamin D3 (cholecalciferol) | Intervention Type: DIETARY_SUPPLEMENT; Name: Vitamin D3 (cholecalciferol); Assigned to Arm(s): Group B, Group C, Group D, Group E | Intervention Type: DIETARY_SUPPLEMENT; Name: Placebo; Assigned to Arm(s): Group A, Group B, Group C, Group D

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Randomized Trial: Maternal Vitamin D Supplementation to Prevent Childhood Asthma (VDAART)
Brief Summary: Vitamin D supplementation given to pregnant women will prevent asthma in their offspring and children.


Options:
A: Arm Label: Vitamin D treatment; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Vitamin D 3 cholecalciferol, Dietary Supplement: Vitamin D3 | Arm Label: placebo; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: Vitamin D3 | Intervention Type: DIETARY_SUPPLEMENT; Name: Vitamin D 3 cholecalciferol; Assigned to Arm(s): Vitamin D treatment | Intervention Type: DIETARY_SUPPLEMENT; Name: Vitamin D3; Assigned to Arm(s): Vitamin D treatment, placebo
B: Arm Label: Vitamin D3 (cholecalciferol); Type: EXPERIMENTAL; Interventions: Dietary Supplement: Vitamin D3 (cholecalciferol) | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Intervention Type: DIETARY_SUPPLEMENT; Name: Vitamin D3 (cholecalciferol); Assigned to Arm(s): Vitamin D3 (cholecalciferol) | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: 400 IU Vitamin D3; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: 400 IU vitamin D3 | Arm Label: 2,000 IU Vitamin D3; Type: EXPERIMENTAL; Interventions: Dietary Supplement: 2,000 IU Vitamin D3 | Intervention Type: DIETARY_SUPPLEMENT; Name: 400 IU vitamin D3; Assigned to Arm(s): 400 IU Vitamin D3 | Intervention Type: DIETARY_SUPPLEMENT; Name: 2,000 IU Vitamin D3; Assigned to Arm(s): 2,000 IU Vitamin D3
D: Arm Label: Vitamin D3; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Vitamin D3 | Arm Label: Control; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: Placebo control | Intervention Type: DIETARY_SUPPLEMENT; Name: Vitamin D3; Assigned to Arm(s): Vitamin D3 | Intervention Type: DIETARY_SUPPLEMENT; Name: Placebo control; Assigned to Arm(s): Control

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: AG-013736 (AXITINIB) FOR THE TREATMENT OF METASTATIC RENAL CELL CANCER
Brief Summary: The study is designed to demonstrate that axitinib (AG-013736) is superior to sorafenib in delaying tumor progression in patients with metastatic renal cell cancer.


Options:
A: Arm Label: Nintedanib (BIBF 1120); Type: EXPERIMENTAL; Interventions: Drug: BIBF 1120 | Arm Label: sunitinib; Type: ACTIVE_COMPARATOR; Interventions: Drug: sunitinib | Intervention Type: DRUG; Name: BIBF 1120; Assigned to Arm(s): Nintedanib (BIBF 1120) | Intervention Type: DRUG; Name: sunitinib; Assigned to Arm(s): sunitinib
B: Arm Label: Arm S: Nivolumab + Sunitinib; Type: EXPERIMENTAL; Interventions: Biological: Nivolumab, Drug: Sunitinib | Arm Label: Arm P: Nivolumab + Pazopanib; Type: EXPERIMENTAL; Interventions: Biological: Nivolumab, Biological: Pazopanib | Arm Label: Arm I-1: Nivolumab + Ipilimumab; Type: EXPERIMENTAL; Interventions: Biological: Nivolumab, Biological: Ipilimumab | Arm Label: Arm I-3: Nivolumab + Ipilimumab; Type: EXPERIMENTAL; Interventions: Biological: Nivolumab, Biological: Ipilimumab | Arm Label: Arm IN-3: Nivolumab+Ipilimumab; Type: EXPERIMENTAL; Interventions: Biological: Nivolumab, Biological: Ipilimumab | Intervention Type: BIOLOGICAL; Name: Nivolumab; Assigned to Arm(s): Arm I-1: Nivolumab + Ipilimumab, Arm I-3: Nivolumab + Ipilimumab, Arm IN-3: Nivolumab+Ipilimumab, Arm P: Nivolumab + Pazopanib, Arm S: Nivolumab + Sunitinib | Intervention Type: BIOLOGICAL; Name: Pazopanib; Assigned to Arm(s): Arm P: Nivolumab + Pazopanib | Intervention Type: DRUG; Name: Sunitinib; Assigned to Arm(s): Arm S: Nivolumab + Sunitinib | Intervention Type: BIOLOGICAL; Name: Ipilimumab; Assigned to Arm(s): Arm I-1: Nivolumab + Ipilimumab, Arm I-3: Nivolumab + Ipilimumab, Arm IN-3: Nivolumab+Ipilimumab
C: Arm Label: A; Type: EXPERIMENTAL; Interventions: Drug: Axitinib (AG-013736) | Arm Label: B; Type: ACTIVE_COMPARATOR; Interventions: Drug: Sorafenib | Intervention Type: DRUG; Name: Axitinib (AG-013736); Assigned to Arm(s): A | Intervention Type: DRUG; Name: Sorafenib; Assigned to Arm(s): B
D: Arm Label: Tivozanib hydrochloride; Type: EXPERIMENTAL; Interventions: Drug: Tivozanib hydrochloride | Arm Label: Sorafenib; Type: ACTIVE_COMPARATOR; Interventions: Drug: Sorafenib | Intervention Type: DRUG; Name: Tivozanib hydrochloride; Assigned to Arm(s): Tivozanib hydrochloride | Intervention Type: DRUG; Name: Sorafenib; Assigned to Arm(s): Sorafenib

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: AG-013736 (AXITINIB) FOR THE TREATMENT OF METASTATIC RENAL CELL CANCER
Brief Summary: The study is designed to demonstrate that axitinib (AG-013736) is superior to sorafenib in delaying tumor progression in patients with metastatic renal cell cancer.


Options:
A: Arm Label: Arm A: Nivolumab 3 mg/kg + Ipilimumab 1 mg/kg; Type: EXPERIMENTAL; Interventions: Biological: Nivolumab, Biological: Ipilimumab | Arm Label: Arm B: Sunitinib 50 mg; Type: ACTIVE_COMPARATOR; Interventions: Biological: Nivolumab, Biological: Ipilimumab, Drug: Sunitinib | Intervention Type: BIOLOGICAL; Name: Nivolumab; Assigned to Arm(s): Arm A: Nivolumab 3 mg/kg + Ipilimumab 1 mg/kg, Arm B: Sunitinib 50 mg | Intervention Type: BIOLOGICAL; Name: Ipilimumab; Assigned to Arm(s): Arm A: Nivolumab 3 mg/kg + Ipilimumab 1 mg/kg, Arm B: Sunitinib 50 mg | Intervention Type: DRUG; Name: Sunitinib; Assigned to Arm(s): Arm B: Sunitinib 50 mg
B: Arm Label: Lenvatinib; Type: EXPERIMENTAL; Interventions: Drug: Lenvatinib | Arm Label: Lenvatinib plus Everolimus; Type: EXPERIMENTAL; Interventions: Drug: Lenvatinib, Drug: Everolimus | Arm Label: Everolimus; Type: ACTIVE_COMPARATOR; Interventions: Drug: Everolimus | Intervention Type: DRUG; Name: Lenvatinib; Assigned to Arm(s): Lenvatinib, Lenvatinib plus Everolimus | Intervention Type: DRUG; Name: Everolimus; Assigned to Arm(s): Everolimus, Lenvatinib plus Everolimus
C: Arm Label: Avelumab in combination with axitinib; Type: EXPERIMENTAL; Interventions: Drug: Avelumab (MSB0010718C), Drug: Axitinib (AG-013736) | Arm Label: Sunitinib; Type: ACTIVE_COMPARATOR; Interventions: Drug: Sunitinib | Intervention Type: DRUG; Name: Avelumab (MSB0010718C); Assigned to Arm(s): Avelumab in combination with axitinib | Intervention Type: DRUG; Name: Axitinib (AG-013736); Assigned to Arm(s): Avelumab in combination with axitinib | Intervention Type: DRUG; Name: Sunitinib; Assigned to Arm(s): Sunitinib
D: Arm Label: A; Type: EXPERIMENTAL; Interventions: Drug: Axitinib (AG-013736) | Arm Label: B; Type: ACTIVE_COMPARATOR; Interventions: Drug: Sorafenib | Intervention Type: DRUG; Name: Axitinib (AG-013736); Assigned to Arm(s): A | Intervention Type: DRUG; Name: Sorafenib; Assigned to Arm(s): B

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Closed-Loop Delivery of Propofol and Remifentanil: Sparing Effect of Dexmedetomidine
Brief Summary: The main objective if to evaluate the sparing effect of dexmedetomidine on the doses of propofol and remifentanil.


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Dexmedetomidine | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Propofol | Intervention Type: DRUG; Name: Dexmedetomidine; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Propofol; Assigned to Arm(s): 2
B: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: NaCl 9/00 | Arm Label: dexmedetomidine; Type: EXPERIMENTAL; Interventions: Drug: dexmedetomidine | Intervention Type: DRUG; Name: NaCl 9/00; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: dexmedetomidine; Assigned to Arm(s): dexmedetomidine
C: Arm Label: Dexmedetomidine; Type: EXPERIMENTAL; Interventions: Drug: Dexmedetomidine HCL Injection | Arm Label: Placebo (PBO); Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Dexmedetomidine HCL Injection; Assigned to Arm(s): Dexmedetomidine | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo (PBO)
D: Arm Label: Balanced Anesthesia; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: NoNarc TIVA; Type: ACTIVE_COMPARATOR; Interventions: Drug: TIVA NoNarc | Intervention Type: DRUG; Name: TIVA NoNarc; Assigned to Arm(s): NoNarc TIVA

Answer: B